Latest News on LENZ

Financial News Based On Company


Advertisement
Advertisement

Gene Therapy for SCID Market is Expected to Reach at a US$ 2.0 Billion by 2034 | Fact.MR Report

https://www.benzinga.com/pressreleases/24/11/g41935864/gene-therapy-for-scid-market-is-expected-to-reach-at-a-us-2-0-billion-by-2034-fact-mr-report
Rockville, MD, Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- According to Fact.MR, a market research and competitive intelligence provider, the global gene therapy for SCID market is projected to grow at a robust CAGR and could reach US$ 2.0 billion by 2034.

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

https://www.globenewswire.com/news-release/2024/09/16/2946330/0/en/MaxCyte-Signs-Strategic-Platform-License-with-Kamau-Therapeutics-to-Accelerate-the-Development-of-Cell-Therapies-for-Genetic-Diseases.html
Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair ( HDR ) novel gene correction technology Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support its homology-directed repair ( HDR ) novel gene ...

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases - MaxCyte ( NASDAQ:MXCT )

https://www.benzinga.com/pressreleases/24/09/g40871379/maxcyte-signs-strategic-platform-license-with-kamau-therapeutics-to-accelerate-the-development-of-
ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 ( GLOBE NEWSWIRE ) -- MaxCyte, Inc., MXCTMXCT ) ) , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based ...

Blindness-Focused LENZ Therapeutics' Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says - LENZ Therapeutics ( NASDAQ:LENZ )

https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38190459/blindness-focused-lenz-therapeutics-investigational-eye-drop-ready-to-revolutionize
Last week, LENZ Therapeutics Inc LENZ released topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101.
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion